Precision’s Exciting HBV Trial: A Breakthrough for Hepatitis B Patients
Precision BioSciences has submitted Clinical Trial Applications (CTAs) to initiate a Phase 1 study for its in vivo gene...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Precision BioSciences has submitted Clinical Trial Applications (CTAs) to initiate a Phase 1 study for its in vivo gene...
The U.S. FDA issued a draft guidance document, “Processes and Practices Applicable to Bioresearch Monitoring (BIMO) Inspections,” to streamline...
BioAlberta has partnered with AxialBridge to support Alberta biotech and MedTech companies in expanding their clinical trials and R&D...
INBRAIN Neuroelectronics has made history by performing the world’s first human procedure using its cortical brain-computer interface (BCI) in...
Vivani Medical announces the approval of its clinical trial for a miniature GLP-1 implant, designed to offer comparable effectiveness...
AstraZeneca’s TAGRISSO (osimertinib) has received US approval for treating adults with unresectable, Stage III EGFR-mutated non-small cell lung cancersmall...
Bayer submitted a supplemental application to the FDA for NUBEQA, an oral androgen receptor inhibitor combined with androgen deprivation...
Enterprise Therapeutics, a biotechnology company specializing in respiratory disease therapies, has earned the “rare pediatric disease designation” (RPD) for...
Bristol Myers Squibb’s COBENFY has received FDA approval for treating adult schizophrenia. As a first-of-its-kind medication, COBENFY adopts a...
The Office for Human Research Protections (OHRP) recently hosted its 7th exploratory workshop, focusing on the increasingly pervasive topic...